Comprehensive Stock Comparison
Compare Immunovant, Inc. (IMVT) vs Apple Inc. (AAPL) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Stability / Safety | IMVT | Beta 1.08 vs AAPL's 1.28, lower leverage |
| Dividends | AAPL | 0.4% yield; 14-year raise streak; IMVT pays no meaningful dividend |
| Momentum (1Y) | IMVT | +34.6% vs AAPL's +9.7% |
| Efficiency (ROA) | AAPL | 31.1% ROA vs IMVT's -44.1% |
Who Each Stock Is For
Income & stability
Growth exposure
Long-term compounding (10Y)
Sleep-well-at-night portfolio
Defensive / Recession hedge
Business Model
What each company does and how it makes money
Immunovant is a clinical-stage biopharmaceutical company developing monoclonal antibody therapies for autoimmune diseases. It generates no current revenue but aims to monetize through future drug sales if its lead candidate batoclimab — currently in Phase II trials for multiple autoimmune conditions — gains regulatory approval. The company's key advantage lies in its novel FcRn inhibitor technology platform, which could offer improved safety and efficacy profiles compared to existing autoimmune treatments.
Apple is a technology giant that designs and sells premium consumer electronics — most famously the iPhone — along with related software and services. It generates revenue primarily from hardware sales (roughly 80% of total) and a fast-growing services segment (around 20%) that includes the App Store, subscriptions, and licensing. Its key competitive advantage is a powerful ecosystem that locks users into its hardware, software, and services through seamless integration and high switching costs.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
IMVT leads in 3 of 6 categories (Financial Metrics, Valuation Metrics). AAPL leads in 2 (Profitability & Efficiency, Total Returns).
Financial Metrics (TTM)
AAPL and IMVT operate at a comparable scale, with $435.6B and $0 in trailing revenue.
| Metric | IMVTImmunovant, Inc. | AAPLApple Inc. |
|---|---|---|
| RevenueTrailing 12 months | $0 | $435.6B |
| EBITDAEarnings before interest/tax | -$487M | $152.9B |
| Net IncomeAfter-tax profit | -$464M | $117.8B |
| Free Cash FlowCash after capex | -$423M | $123.3B |
| Gross MarginGross profit ÷ Revenue | — | +47.3% |
| Operating MarginEBIT ÷ Revenue | — | +32.4% |
| Net MarginNet income ÷ Revenue | — | +27.0% |
| FCF MarginFCF ÷ Revenue | — | +28.3% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +15.7% |
| EPS Growth (YoY)Latest quarter vs prior year | +19.7% | +18.3% |
Valuation Metrics
| Metric | IMVTImmunovant, Inc. | AAPLApple Inc. |
|---|---|---|
| Market CapShares × price | $5.6B | $3.88T |
| Enterprise ValueMkt cap + debt − cash | $4.9B | $3.97T |
| Trailing P/EPrice ÷ TTM EPS | -10.16x | 35.41x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 31.15x |
| PEG RatioP/E ÷ EPS growth rate | — | 1.98x |
| EV / EBITDAEnterprise value multiple | — | 27.45x |
| Price / SalesMarket cap ÷ Revenue | — | 9.33x |
| Price / BookPrice ÷ Book value/share | 5.94x | 53.76x |
| Price / FCFMarket cap ÷ FCF | — | 39.33x |
Profitability & Efficiency
AAPL delivers a 133.5% return on equity — every $100 of shareholder capital generates $134 in annual profit, vs $-47 for IMVT. IMVT carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to AAPL's 1.67x. On the Piotroski fundamental quality scale (0–9), AAPL scores 7/9 vs IMVT's 2/9, reflecting strong financial health.
| Metric | IMVTImmunovant, Inc. | AAPLApple Inc. |
|---|---|---|
| ROE (TTM)Return on equity | -47.1% | +133.5% |
| ROA (TTM)Return on assets | -44.1% | +31.1% |
| ROICReturn on invested capital | — | +64.5% |
| ROCEReturn on capital employed | -66.1% | +69.6% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 7 |
| Debt / EquityFinancial leverage | 0.00x | 1.67x |
| Net DebtTotal debt minus cash | -$714M | $89.7B |
| Cash & Equiv.Liquid assets | $714M | $33.5B |
| Total DebtShort + long-term debt | $98,000 | $123.3B |
| Interest CoverageEBIT ÷ Interest expense | — | — |
Total Returns (with DRIP)
A $10,000 investment in AAPL five years ago would be worth $21,049 today (with dividends reinvested), compared to $18,673 for IMVT. Over the past 12 months, IMVT leads with a +34.6% total return vs AAPL's +9.7%. The 3-year compound annual growth rate (CAGR) favors AAPL at 21.9% vs IMVT's 16.7% — a key indicator of consistent wealth creation.
| Metric | IMVTImmunovant, Inc. | AAPLApple Inc. |
|---|---|---|
| YTD ReturnYear-to-date | +7.0% | -2.4% |
| 1-Year ReturnPast 12 months | +34.6% | +9.7% |
| 3-Year ReturnCumulative with dividends | +58.7% | +81.2% |
| 5-Year ReturnCumulative with dividends | +86.7% | +110.5% |
| 10-Year ReturnCumulative with dividends | +178.7% | +1027.4% |
| CAGR (3Y)Annualised 3-year return | +16.7% | +21.9% |
Risk & Volatility
IMVT is the less volatile stock with a 1.08 beta — it tends to amplify market swings less than AAPL's 1.28 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. IMVT currently trades 94.8% from its 52-week high vs AAPL's 91.5% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | IMVTImmunovant, Inc. | AAPLApple Inc. |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.08x | 1.28x |
| 52-Week HighHighest price in past year | $29.25 | $288.61 |
| 52-Week LowLowest price in past year | $12.72 | $169.21 |
| % of 52W HighCurrent price vs 52-week peak | +94.8% | +91.5% |
| RSI (14)Momentum oscillator 0–100 | 58.1 | 57.5 |
| Avg Volume (50D)Average daily shares traded | 1.2M | 40.9M |
Analyst Outlook
Wall Street rates IMVT as "Buy" and AAPL as "Buy". Consensus price targets imply 28.6% upside for IMVT (target: $36) vs 14.7% for AAPL (target: $303). AAPL is the only dividend payer here at 0.39% yield — a key consideration for income-focused portfolios.
| Metric | IMVTImmunovant, Inc. | AAPLApple Inc. |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $35.67 | $303.11 |
| # AnalystsCovering analysts | 23 | 109 |
| Dividend YieldAnnual dividend ÷ price | — | +0.4% |
| Dividend StreakConsecutive years of raises | — | 14 |
| Dividend / ShareAnnual DPS | — | $1.03 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +2.3% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Mar 20 | Feb 26 | Change |
|---|---|---|---|
| Immunovant, Inc. (IMVT) | 100 | 161.29 | +61.3% |
| Apple Inc. (AAPL) | 100 | 361.46 | +261.5% |
Apple Inc. (AAPL) returned +110% over 5 years vs Immunovant, Inc. (IMVT)'s +87%. A $10,000 investment in AAPL 5 years ago would be worth $21,049 today (including dividends reinvested).
Chart 2Revenue Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Immunovant, Inc. (IMVT) | $0.00 | $0.00 | — |
| Apple Inc. (AAPL) | $215.6B | $416.2B | +93.0% |
Apple Inc.'s revenue grew from $215.6B (2016) to $416.2B (2025) — a 7.6% CAGR.
Chart 3P/E Ratio History — 9 Years
| Stock | 2017 | 2025 | Change |
|---|---|---|---|
| Apple Inc. (AAPL) | 18.4 | 36.4 | +97.8% |
Apple Inc. has traded in a 13x–41x P/E range over 9 years; current trailing P/E is ~35x.
Chart 4EPS Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Immunovant, Inc. (IMVT) | -13.67 | -2.73 | +80.0% |
| Apple Inc. (AAPL) | 2.08 | 7.46 | +258.7% |
Apple Inc.'s EPS grew from $2.08 (2016) to $7.46 (2025) — a 15% CAGR.
Chart 5Free Cash Flow — 5 Years
Immunovant, Inc. generated $-377M FCF in 2025 (-351% vs 2021). Apple Inc. generated $99B FCF in 2025 (+6% vs 2021).
IMVT vs AAPL: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is IMVT or AAPL a better buy right now?
Apple Inc. (AAPL) offers the better valuation at 35.4x trailing P/E (31.1x forward), making it the more compelling value choice. Analysts rate Immunovant, Inc. (IMVT) a "Buy" — based on 23 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — IMVT or AAPL?
Over the past 5 years, Apple Inc. (AAPL) delivered a total return of +110.5%, compared to +86.7% for Immunovant, Inc. (IMVT). A $10,000 investment in AAPL five years ago would be worth approximately $21K today (assuming dividends reinvested). Over 10 years, the gap is even starker: AAPL returned +1027% versus IMVT's +178.7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — IMVT or AAPL?
By beta (market sensitivity over 5 years), Immunovant, Inc. (IMVT) is the lower-risk stock at 1.08β versus Apple Inc.'s 1.28β — meaning AAPL is approximately 18% more volatile than IMVT relative to the S&P 500. On balance sheet safety, Immunovant, Inc. (IMVT) carries a lower debt/equity ratio of 0% versus 167% for Apple Inc. — giving it more financial flexibility in a downturn.
04Which has better profit margins — IMVT or AAPL?
Apple Inc. (AAPL) is the more profitable company, earning 26.9% net margin versus 0.0% for Immunovant, Inc. — meaning it keeps 26.9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AAPL leads at 32.0% versus 0.0% for IMVT. At the gross margin level — before operating expenses — AAPL leads at 46.9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Is IMVT or AAPL more undervalued right now?
Analyst consensus price targets imply the most upside for IMVT: 28.6% to $35.67.
06Which pays a better dividend — IMVT or AAPL?
In this comparison, AAPL (0.4% yield) pays a dividend. IMVT does not pay a meaningful dividend and should not be held primarily for income.
07Is IMVT or AAPL better for a retirement portfolio?
For long-horizon retirement investors, Apple Inc. (AAPL) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1.28), +1027% 10Y return). Both have compounded well over 10 years (AAPL: +1027%, IMVT: +178.7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between IMVT and AAPL?
These companies operate in different sectors (IMVT (Healthcare) and AAPL (Technology)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.